Iterum Therapeutics Plc's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Iterum Therapeutics Plc's ROA in the third quarter of 2025?
Iterum Therapeutics Plc recorded a cumulative net loss of $-27 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -74.78%.

However, within the Healthcare sector 686 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4237, from total ROA ranking in the second quarter of 2025 at 4305.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	103.86 %	139.64 %	67.91 %	69.74 %	-59.87 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-27	-24	-23	-25	-31
Return On Assets (TTM)	-74.78 %	-75.45 %	-83.72 %	-104.91 %	-160.56 %
ITRM's Total Ranking	# 4237	# 4305	# 4439	# 5245	# 4796
Total Assets (TTM) in million	33	34	33	45	16
Seq. Total Assets Change	-4.45 %	3.15 %	-26.04 %	179.67 %	12.32 %
Seq. Net Income Change	-	-	-	-	-

ITRM's 5 Years Annual ROA >> Back to ITRM Management Effectiveness >> Compare ITRM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 316
Sector	# 687
Overall	# 4190

Return On Assets Statistics
High	Average	Low
4.06 %	-111 %	-261.91 %
(Mar 31 2022)		(Mar 31 2021)

Financial Statements
Iterum Therapeutics Plc's Assets	$ 33 million	ITRM's Balance sheet
Iterum Therapeutics Plc's Income	$ -9 million	Quarterly ITRM's Income Statement
ITRM's Income by Division		See ITRM's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	69.74 %	-60.68 %	-26.93 %	179.06 %	27.34 %
Total Assets in million	45	26	67	92	33
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-25	-38	-44	-92	-52
Annual Return On Assets	-55.51 %	-145.94 %	-66.45 %	-100.06 %	-158.59 %

ITRM's 5 Years Annual ROA >> Back to ITRM Management Effectiveness >> Compare ITRM ROA to its Competitors

More Return On Assets Ratios
ITRM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ITRM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ITRM's Competitors
Subscribers only: Roa for Iterum Therapeutics Plc's Suppliers
Subscribers only: Return On Assets for ITRM's Customers

You may also want to know
ITRM's Roi	ITRM's Inventory Turnover Ratio	ITRM's Growth Rates	ITRM's Dividend Comparisons
	ITRM's Profitability Ratios	ITRM's Asset Turnover Ratio	ITRM's Dividend Growth
ITRM's Roe	ITRM's Valuation Ratios	ITRM's Financial Strength Ratios	ITRM's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:34:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.